Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
CytoMed Therapeutics Limited (GDTC)
Company Research
Source: GlobeNewswire
SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced today that the Intellectual Property Corporation of Malaysia has granted a patent for its chimeric antigen receptor gamma delta T cell (“CAR-?d T cell”) technology, which targets solid and hematological tumors. The patent titled “Gamma Delta T Cells and a Method of Augmenting the Tumoricidal Activity of the Same” (Patent number: MY-200528-A) covers technologies for the clinical-scale expansion of ?d T cells from a small amount of donor peripheral blood cells, as well as the modification of the expanded ?d T cells to incorporate a chimeric antigen receptor (“CAR”) that enables the modified cells to recognize a wide range of cancers, including both solid and hematological
Show less
Read more
Impact Snapshot
Event Time:
GDTC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GDTC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GDTC alerts
High impacting CytoMed Therapeutics Limited news events
Weekly update
A roundup of the hottest topics
GDTC
News
- CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage RegenerationAccesswire
- CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesGlobeNewswire
- CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and RepairGlobeNewswire
GDTC
Sec Filings
- 4/25/24 - Form 6-K/A
- 4/24/24 - Form 6-K
- 4/22/24 - Form 20-F
- GDTC's page on the SEC website